Champions Oncology Inc (NASDAQ: CSBR) has experienced a rise in its stock price by 17.94 compared to its previous closing price of 6.27. However, the company has seen a gain of 13.77% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-28 that HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization’s capabilities in the development and assessment of targeted radiotherapeutics.
Is It Worth Investing in Champions Oncology Inc (NASDAQ: CSBR) Right Now?
The price-to-earnings ratio for Champions Oncology Inc (NASDAQ: CSBR) is above average at 16.42x. The 36-month beta value for CSBR is also noteworthy at 0.37. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CSBR is 6.12M, and at present, short sellers hold a 1.56% of that float. The average trading volume of CSBR on June 13, 2025 was 35.66K shares.
CSBR’s Market Performance
The stock of Champions Oncology Inc (CSBR) has seen a 13.77% increase in the past week, with a 18.41% rise in the past month, and a -16.82% fall in the past quarter. The volatility ratio for the week is 9.86%, and the volatility levels for the past 30 days are at 5.74% for CSBR. The simple moving average for the past 20 days is 18.32% for CSBR’s stock, with a 6.03% simple moving average for the past 200 days.
Analysts’ Opinion of CSBR
Many brokerage firms have already submitted their reports for CSBR stocks, with Craig Hallum repeating the rating for CSBR by listing it as a “Buy.” The predicted price for CSBR in the upcoming period, according to Craig Hallum is $6 based on the research report published on September 12, 2024 of the previous year 2024.
CSBR Trading at 7.76% from the 50-Day Moving Average
After a stumble in the market that brought CSBR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.32% of loss for the given period.
Stock Fundamentals for CSBR
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.52 for the gross margin
The net margin for Champions Oncology Inc stands at 0.11. The total capital return value is set at 0.63. Equity return is now at value 376.84, with 22.39 for asset returns.
Based on Champions Oncology Inc (CSBR), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2.
Currently, EBITDA for the company is -5.05 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 1.8. The receivables turnover for the company is 3.71for trailing twelve months and the total asset turnover is 1.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
In summary, Champions Oncology Inc (CSBR) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
